Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AURA vs TBPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: AURA 1 – 5 TBPH Matrix Metrics: AURA 2 – 8 TBPH

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin).

  • Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. AURA 31.1/100 SELL) and 0.48β · 2% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AURA vs TBPH
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 8.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.3 · SMA20: $6.66 · SMA50: $6.54
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96

6-Pillar Scorecard Institutional Category Breakdown (AURA 1 – 5 TBPH)

Columns: Metric · AURA · TBPH
1. Valuation Multiples TBPH
Forward P/E N/M 13.4x
Trailing P/E N/M 16.4x
PEG Ratio N/M N/M
EV / Revenue N/M 8.5x
2. Growth & Scale TBPH
Revenue Growth (YoY) +0.0% -20.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $104M
Market Cap $728.6M $884.2M
3. Profitability & Quality TBPH
Gross Margin N/A 75.1%
Operating Margin 0.0% 8.9%
Net Profit Margin 0.0% 51.6%
Return on Equity (ROE) -61.7% 20.9%
4. Balance Sheet & Cash Flow TBPH
Cash Generation (TTM) -$110M $11M EBITDA
Cash Flow Margin N/A 10.6% EBITDA Mgn
Net Cash / Leverage $26M Net Cash $5.58 Book/Sh · 20.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AURA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 160.1% (22nd %ile) 55.0% (16th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity N/A 66.2% of Rev ($69M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AURA (2) vs TBPH (8)
Institutional Metric AURA TBPH Criterion Row Edge
Market Capitalization
Scale
$728.6M $884.2M Larger Scale TBPH
Trailing P/E Ratio
Valuation
N/M 16.4x Lower Multiple TBPH
Forward P/E Ratio
Valuation
N/M 13.4x Lower Multiple TBPH
Revenue Growth (YoY)
Growth
+0.0% -20.9% Higher Growth AURA
Operating Margin (TTM)
Profitability
0.0% 8.9% Higher Margin TBPH
Net Profit Margin
Profitability
0.0% 51.6% Higher Margin TBPH
Return on Equity (ROE)
Capital Efficiency
-61.7% 20.9% Higher ROE TBPH
52-Week Range Position
Momentum
52% ($5–$10) 50% ($13–$21) Stronger Trend AURA
Beta / 30D Volatility
Risk Regime
0.92β · 75% Vol 0.48β · 2% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 54.9 / 100 (HOLD) Higher Composite TBPH
Trailing 12M Revenue (USD)
Operating Scale
N/A $104M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 75.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($26M Net Cash) $11M EBITDA ($5.58 Book/Sh · 20.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TBPH +23.92 pp
AURA: -23.8% · TBPH: +0.12%
3M Horizon TBPH +13.1 pp
AURA: -14.49% · TBPH: -1.39%
6M Horizon TBPH +18.9 pp
AURA: -4.6% · TBPH: +14.3%
1Y Horizon AURA +13.99 pp
AURA: +8.86% · TBPH: -5.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs TBPH. Trailing 12-month operating profitability (AURA 0.0% vs TBPH 8.9%) and valuation multiples (AURA N/M vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M
TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published

Investor FAQ AURA vs TBPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin). Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. AURA 31.1/100 SELL) and 0.48β · 2% Vol risk profile, whereas AURA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

TBPH leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TBPH at -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $104M for TBPH. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($69M) (0 disclosures) for TBPH.

TBPH screens cheaper on headline valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus TBPH (20.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.